Related Experiment Video
Updated: Jul 13, 2026
10:25
Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System
Published on: September 20, 2019
Transforming growth factor-beta(2) polymorphisms are associated with childhood atopic asthma
K Hatsushika1, T Hirota, M Harada
1Department of Immunology, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan.
Summary
Genetic variations in transforming growth factor beta 2 (TGF-beta(2)) are linked to childhood atopic asthma risk in Japanese children. These TGF-beta(2) gene polymorphisms may influence asthma development and susceptibility.
Area of Science:
- Genetics
- Immunology
- Pediatrics
Background:
- Transforming growth factor beta (TGF-beta) regulates airway inflammation and remodeling in asthma.
- TGF-beta(2) is a predominant isoform in severe asthma, linked to airway remodeling.
Purpose of the Study:
- To investigate the association between TGF-beta(2) gene polymorphisms and childhood atopic bronchial asthma in a Japanese population.
Main Methods:
- Identified eight polymorphisms and performed linkage disequilibrium mapping of the TGF-beta(2) gene.
- Genotyped three variants in the promoter and 3'UTR and conducted an association study.
- Performed association analysis, expression analysis, and functional analysis.
Main Results:
- The 3'UTR 94862T >A variant and the -109-->ACAA ins promoter variant were significantly associated with childhood atopic asthma risk.
- TGF-beta(2) expression was detected in bronchial epithelium.
- The promoter variant -109-->ACAA ins increased TGF-beta(2) promoter-reporter activity.
Conclusions:
- Functional genetic polymorphisms in TGF-beta(2) suggest its involvement in childhood atopic asthma development.
- TGF-beta(2) polymorphisms may be important for understanding childhood asthma susceptibility.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:20Asthma: Pathogenesis and Management
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...